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Bone sarcoma patient-derived 
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Standard therapy of osteosarcoma (oS) and ewing sarcoma (eW) rests on cytotoxic regimes, which 
are largely unsuccessful in advanced patients. preclinical models are needed to break this impasse. A 
panel of patient-derived xenografts (pDX) was established by implantation of fresh, surgically resected 
osteosarcoma (OS) and Ewing sarcoma (EW) in NSG mice. Engraftment was obtained in 22 of 61 OS 
(36%) and 7 of 29 EW (24%). The success rate in establishing primary cell cultures from OS was lower 
than the percentage of pDX engraftment in mice, whereas the reverse was observed for eW; the 
implementation of both in vivo and in vitro seeding increased the proportion of patients yielding at 
least one workable model. the establishment of in vitro cultures from PDX was highly efficient in both 
tumor types, reaching 100% for EW. Morphological and immunohistochemical (SATB2, P-glycoprotein 
1, CD99, caveolin 1) studies and gene expression profiling showed a remarkable similarity between 
patient’s tumor and pDX, which was maintained over several passages in mice, whereas cell cultures 
displayed a lower correlation with human samples. Genes differentially expressed between OS original 
tumor and PDX mostly belonged to leuykocyte-specific pathways, as human infiltrate is gradually 
replaced by murine leukocytes during growth in mice. In EW, which contained scant infiltrates, no gene 
was differentially expressed between the original tumor and the PDX. A novel therapeutic combination 
of anti-CD99 diabody C7 and irinotecan was tested against two EW PDX; both drugs inhibited PDX 
growth, the addition of anti-CD99 was beneficial when chemotherapy alone was less effective. The 
panel of oS and eW pDX faithfully mirrored morphologic and genetic features of bone sarcomas, 
representing reliable models to test therapeutic approaches.
Osteosarcoma (OS) and Ewing sarcoma (EW), the two most common primary tumors of bone, are high-grade 
malignant neoplasms with very aggressive behavior and high tendency to form metastasis; they arise frequently 
in children and remain prominent among teenagers and young adults1–4.
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Patients are still treated with conventional therapies comprising a combination of high-dose multidrug 
chemotherapy associated with local control of the tumor by surgery and/or radiotherapy1,3,5. As a consequence 
of this multimodal treatment, patients with localized disease at diagnosis have a 5-year survival rate of nearly 
65% for OS and 70% for EW4,6. However, patients with disseminated disease at diagnosis and patients who fail 
first-line treatment have survival rates as low as 30–35%2,7. Furthermore, heavy side effects severely compromise 
the quality of life in these young patients. There is a strong demand from patients, families and oncologists of 
therapies with improved efficacy and reduced side effects.
Any further improvement in the design of innovative therapeutic approaches requires a better understanding 
of tumor evolution, development of drug resistance and the testing of new compounds in appropriate experi-
mental models8–12. Recently the development of patient-derived xenografts (PDXs) obtained by direct implant of 
surgically resected tumors in immunodeficient mice, has offered a more accurate and reliable preclinical model 
of cancer9,13–18. We present here a new large panel of OS and EW PDX and primary cell cultures obtained from 
patients treated at IRCCS Istituto Ortopedico Rizzoli, and we show that PDX faithfully mirror the molecular and 
cellular phenotype of the original human tumor.
Methods
tissue sampling. Tumor samples were obtained from surgical specimens under sterile conditions. Whenever 
sample size was deemed to be sufficient, the available material was split into four parts and processed as follows: 
(1) the tissue to be implanted in immunodeficient mice for the generation of PDX was placed in Iscove’s Modified 
Dulbecco’s Medium (IMDM) supplemented with 10% Fetal Bovine Serum (FBS) (Euroclone) and antibiotics 
(penicillin, streptomycin), hereafter referred to as complete medium; (2) tissue for genetic analyses was frozen in 
liquid nitrogen and stored at −80 °C; (3) tissue for histopathology and immunohistochemistry was fixed in a 10% 
formalin solution; (4) any remaining tissue was used for in vitro cultures (see below).
Mice and establishment of pDX. Immunodeficient NOD Scid gamma (NSG) mice were bred under ster-
ile conditions in our animal facilities from founders originally obtained from Charles River, Italy. To generate 
PDXs, a fresh tumor specimen measuring approximately 4 mm3 was implanted subcutaneously (s.c.) at the level 
of trans-scapular brown fat of 5–11-week-old NSG male mice within an average of 1–2 hours following patient’s 
surgery. Tumor growth was monitored at least twice weekly using calipers until it reached a maximal volume of 
2.5 cm3, then the mouse was sacrificed by CO2 inhalation and cervical dislocation, the tumor was removed, and 
an accurate necropsy was performed to assess metastatic spread. The tumor was minced with scissors and tumor 
fragments were implanted in NSG mice; the remaining fragments were immersed in 90% FBS + 10% DMSO for 
viable storage in liquid nitrogen or used for histopathological and molecular analyses.
Growth of established pDX in different immunodeficient mice. Established PDXs were also 
implanted in 5-11-week-old BALB/c Rag2−/−; Il2rg−/− (hereafter referred to as RGKO) mice bred in our 
animal facilities from founders kindly given to us by Drs. T. Nomura and M. Ito of the Central Institute for 
Experimental Animals (Kawasaki, Japan)19. Equal amounts of PDX fragments, obtained as described above from 
tumors grown in NSG mice, were implanted in parallel in RGKO mice and in NSG mice. Tumor growth was 
measured as described above.
primary patient-derived or pDX-derived cell lines. Tissue samples obtained from the patient or from 
a PDX were minced into small pieces and placed in complete medium into 60-mm dishes (Falcon) incubated at 
37 °C in a 5% CO2 humified atmosphere. When the outgrowth cultures formed a confluent monolayer, the cells 
were sub-cultured after enzymatic removal with 0.05% trypsin-EDTA and maintained in vitro for at least 10 pas-
sages, before being processed for in vitro studies. Cell lines were authenticated through STR analysis (PowerPlex 
ESX Fast System, Promega) in comparison to the profile of the original surgical specimen and of the PDX when 
appropriate, moreover the human origin of in vitro cultures was confirmed by PCR analysis with species-specific 
primers.
Histopathology and immunohistochemistry. The tissues were fixed in 10% buffered formalin, routinely 
processed, and embedded in paraffin. Serial, 3-μm-thick, paraffin sections mounted on pre-coated slides were 
processed according to standardized automated procedures (Ventana Medical Systems, Tucson AZ, USA), and 
immunostained with the following antibodies: CD99 (Ventana, Mouse Monoclonal antibody O13, pre-diluted), 
SATB2 (Santa Cruz Biotechnology, Mouse Monoclonal antibody SATBA4B10, 1:200 dilution), RUNX2 (Santa 
Cruz Biotechnologies, SC-101145 27-K 1:10 dilution), caveolin-1 (BD - Transduction Labs, 610058 1:500 dilu-
tion), anti MDR1 P-gp (ABCB1), clone JSB-1 (Monosan - MON9011-1 1:50 diluition), or with buffer alone (neg-
ative control). Pretreatment for antigen retrieval was performed at 95 °C with Tris-EDTA, pH 8.00 for 20 minutes. 
Staining was performed with the UltraView Universal DAB Detection Kit (Ventana Medical Systems, Tucson 
AZ, USA). Appropriate positive and negative controls were included in each run, furthermore all stained sec-
tions included non-tumor mouse cells, such as endothelial cell, myopericytes and fibroblasts which were invari-
ably negative (see Fig. 1). For morphological analyses the slides were stained with haematoxylin, rehydrated and 
coverslipped.
Whole gene expression analysis. RNA from 9 EW and 11 OS samples was hybridized on Agilent whole 
human genome microarray (#G4851C, Agilent Technologies), which represents 60k unique human transcripts. 
Gene expression analysis was conducted on PDXs that were representative of the major clinical variables under 
study, i.e. pediatric and adult cases, treated and untreated cases, primary, relapsed and metastatic cases, in all 
instances selecting a PDX that had yielded an in vitro culture (see Supplementary Table 1). One-color gene expres-
sion was performed according to the manufacturer’s procedure. Briefly, RNA quality was assessed by Agilent 
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Bioanalyzer to have a RIN (RNA integrity number) higher than 7. Labeled cRNA was synthesized from 100 ng 
of total RNA using the Low Input Quick-Amp Labeling Kit, one color (Agilent Technologies) in the presence of 
cyanine 3-CTP. Hybridization was performed at 65 °C for 17 hours in a rotating oven. Images at 5 µm (3 µm) res-
olution were generated by Agilent scanner, Feature Extraction 10.7.3.1 software (Agilent Technologies) was used 
to obtain the microarray raw-data. Data are deposited in the ArrayExpress database (accession E-MTAB-7568).
Bioinformatic data analysis. Data were normalized and analyzed using GeneSpring GX v.14.8 software 
(Agilent Technologies). Data transformation was applied to set all the negative raw values at 1.0, then the quin-
tile normalization was applied. The probes detected in at least one sample were used for statistical analyses. 
Unsupervised principal component analysis and correlation analysis (Pearson’s correlation) were performed to 
assess sample similarity and to assess the global gene expression profile of PDX models. Differentially expressed 
genes were selected to have a ≥2-fold expression difference between matching PDX and primaries and an adjusted 
p-value ≤ 0.05 at paired t-test, with Benjamini and Hoechberg correction for false positive reduction. Hierarchical 
clustering was performed for OS samples with GeneSpring clustering tool using the list of differentially expressed 
genes and the Manhattan correlation as a measure of similarity. Pathway and network analysis of differentially 
expressed genes was determined using the web-based software MetaCore (GeneGo, Thomson Reuters).
Sanger analysis of TP53 mutational status and assessment of fusion transcripts. DNA or 
RNA was extracted from the original tumor or from PDX samples using standard DNAzol or TRIzol proce-
dure (Thermo Fisher Scientific, Foster City, CA, USA). Nucleic acid quality and concentration were evaluated 
by Nanodrop (Thermo Fisher Scientific). DNA aliquots of 20 µl at the concentration of 12 ng/µl for each sample 
were used for genotyping analysis of the TP53 mutational status, performed by mean of Sanger Sequencing on an 
ABI3130xl platform using the BigDye Terminator 3.1 technology (Life Technologies, Carlsbad, CA, USA) ampli-
fying exons together with exon-intron boundaries. The obtained sequence was compared to the NCBI RefSeq 
Figure 1. Histologic and immunohistochemical features of patients’ tumors and corresponding PDX at 
different in vivo passages. OS sections were stained with hematoxylin and eosin (H&E) or with antibodies 
against OS biomarkers SATB2 and PGP. PDXs closely resembles patient’s tumor, including the production 
of neoplastic bone and the presence of anaplastic cells. SATB2 and PGP expression of PDX mirrored that of 
patient’s tumor. EW sections were stained with H&E or with antibodies against EW biomarkers CD99 and CAV-
1. EW PDXs consist of small round cell sheets, closely packed and without matrix, resembling patient’s tumors. 
CD99 and CAV-1 expression of PDX mirrored that of patient’s tumor. Bar: 50 μm.
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(NT_010718) using CodonCode Aligner software (CodonCode Corporation, Centerville, MA, USA) and manual 
reading. For identification of EWS-ETS fusion transcripts, 500 ng of total RNA was reverse transcribed according 
the manufacturer’s protocol (High Capacity cDNA Archive Kit, Life Technologies, Carlsbad, CA, USA). cDNA 
was used as template to amplify EWS-ETS fusion transcripts as previously described20. All primer sequences are 
available upon request.
In vivo therapy of pDX-bearing mice. Freshly obtained fragments of established EW PDX were implanted 
s.c. in the scapular region of 6–11-week-old immunodeficient male mice. Pharmacological treatments started 
when tumors reached a volume of 10 mm3, i.e. a mean diameter of 2.7 mm. Animals were randomized to receive 
two cycles of anti-CD99 diabody C7 (dAbd C7)21 peritumorally (Diatheva srl, 1 mg per injection, 5 days/week 
for 2 consecutive weeks followed by one week of rest) plus irinotecan intraperitoneally (Selleckchem, 0.5 mg/kg, 
5 days/week for 1 week, starting after the first week of treatment with dAbd C7); control mice were not treated. 
Tumor size was measured with calipers; tumor volumes were calculated according to the formula π [√(a × b)]3/6, 
where a = maximal tumor diameter and b = tumor diameter perpendicular to a. Mouse body weights and tumor 
volumes were measured at least once a week. Experimental humane endpoint was a tumor maximum volume of 
3 cm3; as soon as an experimental group (usually untreated controls) overcame this threshold, all other groups 
were sacrificed to evaluate metastatic spread under comparable conditions. To compare the slopes of tumor 
growth curves, regression coefficients of linear regressions were calculated and compared pairwise by means of 
the Prism v 7.03 software (GraphPad Software, San Diego, CA).
ethics approval and consent to participate. The collection of human tumor tissue was approved 
by the ethical committee of the IRCCS Istituto Ortopedico Rizzoli (project #0038254, approval with protocol 
0009323) and patient-informed consent forms were obtained for the establishment of PDX models; all methods 
were performed in accordance with institutional guidelines and Italian law. All animal procedures were done in 
accordance with European directive 2010/63/UE and Italian Law (DL 26/2014); experimental protocols were 
reviewed and approved by the institutional animal care and use committee (“Comitato per il Benessere Animale”) 
of the University of Bologna and by the Italian Ministry of Health with letters 782/2015-PR, 208/2017-PR and 
755/2018-PR.
Results
establishment of bone sarcoma pDXs. We implanted in immunodeficient mice 90 primary or meta-
static tumor samples, 61 from OS and 29 from EW patients (analytical data are shown in Supplementary Table 1). 
Successful engraftment was obtained in 36% of OS and 24% of EW samples (Table 1). Of note, extraskeletal OS, 
which have a poorer prognosis than bone OS22, yielded PDX establishment with 100% efficiency, as compared to 
30% for bone OS (Table 1).
No significant difference was observed in engraftment efficiency between OS primary tumors (32%), local 
relapses (57%) and metastases (35%); analogous conclusions held true for EW, even though limited numbers of 
relapses and metastases were available (Table 1). In five OS cases we received more than one specimen from the 
same patient, which included at least one metastatic sample (one primary tumor + metastasis, two cases of local 
relapse + metastasis, two cases of multiple metastases). Only in one case both specimens yielded a PDX, whereas 
in four cases one grew as PDX and the other(s) did not (Supplementary Table 1), leading to the conclusion that 
the ability to engraft was specimen-specific, rather than patient-specific.
Our clinical series contained a mix of pediatric and adult cases, reflecting the cohort of bone sarcoma patients 
admitted to our Institution, thus we compared their engraftment efficiencies. No significant difference was found 
between pediatric and adult tumors (Table 1).
After implantation of the surgical sample in mice, the time required for the appearance of a sizeable tumor 
was highly variable, raging between one week and one year (Table 1). OS patient’s samples generally grew in mice 
significantly faster than EW (9 vs. 27 weeks), however the difference disappeared in subsequent in vivo passages, 
which converged to shorter latency times of the order of 4–5 weeks (Table 1).
We feared that neo-adjuvant cytotoxic therapy, which is frequently administered to OS and EW patients, 
could jeopardize PDX establishment23. We found an opposite trend between the two tumor types. In primary OS 
the specimens obtained after neoadjuvant therapy gave rise to PDX with a lower efficiency than those obtained 
in the absence of therapy (Table 1). On the contrary, no EW specimen from untreated patients produced a PDX 
(Table 1). However, it should be noted that most untreated EW specimens were biopsies, which also failed to yield 
PDXs (Supplementary Table 1), therefore at least two variables (untreated vs. treated and bioptical vs. surgical) 
were at play here, but the numerosity was insufficient for a meaningful stratification of patients.
The level of necrosis induced by therapy was routinely evaluated in all treated patients. In OS patients there 
was no significant difference in the level of necrosis between cases that gave rise to a PDX and cases which failed 
to engraft. In contrast, a significant difference was found between those EW patients from which a PDX was 
obtained, which had a low level of necrosis, and patients which failed to produce a PDX, which had a much higher 
level of necrosis (Table 1).
A notable difference between our sarcoma series and most carcinoma PDX studies was that we did not observe 
any human lymphoma development, a frequent event occurring in one-fourth to one-third of mice receiving 
implants of human carcinomas23–25. As human lymphomas of mice implanted with human solid tumors arise 
from EBV-immortalized human infiltrating lymphocytes growing in the immunodeficient host25, the lack of lym-
phomas in our series could be attributed both to the extreme scarcity of infiltrating lymphocytes in bone sarco-
mas26 and to the young age of patients, which in Western countries have a lower prevalence of EBV positivity than 
adults27.
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We took advantage of the availability in our animal facilities of two popular immunodeficient knockout mice, 
i.e. NSG and RGKO, to directly compare their permissivity to the growth of established human PDX. Overlapping 
growth rates were observed when equal amounts of the same in vivo passage of six OS and three EW PDX were 
implanted in parallel both in NSG and in RGKO (Supplementary Fig. 1), leading to the conclusion that bone sar-
coma PDX established in NSG mice grow equally well in RGKO mice. Other Authors used NSG mice to establish 
human PDX, then switched to nude mice for subsequent passages28. The use of a more robust (and in some instances 
less expensive) mouse host for experiments entailing the use of large numbers of mice could be advantageous.
Table 1. Establishment of bone sarcoma PDX. ♣OS vs EW, χ2 with Yates’s correction. ‡χ2, Yates’s correction. 
●Fisher’s exa ct test. †χ2, 3 × 2 contingency table. ◊OS vs EW, Wilcoxon’s non-parametric test. §Student’s t test. 
*Patient numbers as per “Neo-adjuvant therapy” line above.
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establishment of bone sarcoma cell cultures from clinical samples and from pDXs. We had the 
opportunity to obtain tumor material also to seed in vitro primary cultures from most clinical specimens (73 of 90 
cases), thus enabling us to directly compare the two major ways to establish human tumor models10,17,29.
We found that the rate of success in establishing primary cell cultures from OS tumor samples was lower than 
the percentage of successful PDX engraftment in mice, whereas the reverse was observed for EW (Table 2). In 
both tumor types primary cultures from PDX were established with a significantly higher efficiency than from the 
original specimen, reaching 100% for EW (Table 2).
The overall proportion of clinical specimens yielding primary cultures (24/73, 33%) overlapped that of PDX 
(25/73, 34%), however we found several discordant cases. On the whole, it can be said that the simultaneous 
use of both approaches raised the proportion of cases yielding a viable model (either in vitro or in vivo) from 
one-third to almost one-half (34/73, 47%). The analysis of concordant and discordant cases showed a strong 
imbalance between tumor types. All cases which gave rise to a PDX while failing to produce a primary culture 
were OS (Table 3), thus confirming the propensity of OS to grow in vivo rather than in vitro.
fidelity and stability of bone sarcoma pDX. To compare PDX models and patient’s tumors we per-
formed histological and molecular profiling at different in vivo passages in mice.
A comparative morphological analysis of all xenografts showed that PDX maintained a striking similarity of 
the histological features with those of the patient’s tumors at least until the third transplant generation (see Fig. 1 
for representative pictures). The expression of relevant molecular biomarkers of both tumor types, analyzed in all 
PDXs, was also faithfully mirrored by PDX, in particular SATB2 and PGP in OS PDX (Fig. 1), CD99 and caveolin 
1 in EW PDX (Fig. 1).
Fusion transcripts of EW PDX also mirrored those found in patients (Supplementary Table 2). As TP53 muta-
tions are relatively rare (<10%) in EW30, we compared gene sequences of the patient’s sample and of the PDX, 
because TP53 alterations can arise during the adaptation to in vitro culture of human sarcoma cells, resulting in a 
much higher proportion of cell lines harboring TP53 mutations than actual human tumors31. The results showed 
that de novo TP53 mutations did not arise in EW PDX (Supplementary Table 2), further confirming that PDX 
reliably reproduce the molecular features of the original tumor.
Gene expression profiling. To gain a better insight into the similarity of the PDX with the original tumor, 
we performed a global gene expression correlation analysis between gene expression profiles of primary OS and 
EW samples and the corresponding PDX. Unsupervised clustering using all (40 k) genes and all samples showed 
that each tumor histotype formed a separate cluster, and all samples matching tumors and PDXs derived from 
the same patient clustered together (Fig. 2A). Indeed, the correlation between primary tumors and their PDXs 
was extremely high for both tumor types (Pearson’s r range r = 0.94–0.96), thus confirming the close resemblance 
of PDXs to the original human neoplasm. We included in the analysis two OS PDX at the sixth in vivo passage, 
also in these cases we observed a strong correlation with both the original specimen and the first in vivo passage 
(Fig. 2B,C).
For EW, the comparison of original patient samples with PDXs did not reveal any significant differentially 
expressed gene (fold change >2, adjusted p < 0.05 at paired t-test). On the contrary, the comparison between OS 
primaries and PDX yielded 397 differentially expressed genes (Fig. 3A and Supplementary Table 3).
A Pathway Enrichment Analysis (Metacore software) showed that the genes that differentiate human OS from 











Yes Yes 15 8 (57%) 7 (43%)
No No 39 24 (62%) 15 (38%)
Yes No 9 5 (56%) 4 (44%)
No Yes 10 10 (100%) 0 (0%)
TOTAL 73 47 (64%) 26 (36%)
Table 3. Concordance between successful in vitro culture from patient specimen and successful PDX, by tumor 
type*. *Each line adds to 100%.
Table 2. PDX versus in vitro cell cultures. †χ2, 3 × 2 contingency table.
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that, upon engraftment in the mouse, human leukocytes, which also include lymphocytes, are gradually replaced 
by leukocytes of the immunodeficient host, lacking T, B and NK cells32.
Cell cultures displayed a reduced correlation with the primary tumor if compared to PDX (r = 0.90–0.93, 
Fig. 2), moreover an unsupervised principal Component Analysis revealed a marked difference between OS- and 
EW-derived samples, with a major distance within each group for the primary cell line sample (Supplementary 
Fig. 2), thus indicating that in vitro adaptation has a higher impact on the molecular profile than in vivo growth10. 
Primary cell cultures appeared less reliable than PDX models, a relevant feature especially in OS, that has a high 
level of genetic heterogeneity33,34.
novel chemo-immunotherapeutic combination for the treatment of ewing sarcoma. PDX are 
an ideal model to test therapeutic approaches. We have recently developed dAbd C7, a therapeutic bivalent anti-
body (diabody) against CD9921,35,36, and we were interested in testing combinations with effective drugs in clin-
ical use, such as irinotecan37. PDX-EW#3 and PDX-EW#2 were thus treated with dAbd C7, irinotecan or both. 
While both dAbd C7 and irinotecan effectively hampered tumor growth of both PDXs, the combined treatment 
provided a definite advantage in comparison to single treatments in PDX-EW#3 (Fig. 4). In PDX-EW#2, which 
displayed a faster growth rate than PDX-EW#3, the high effectiveness of irinotecan alone was not significantly 
enhanced by the combined treatment (Fig. 4). Interestingly, we found that 40% (2 of 5) untreated mice bearing 
PDX-EW#3 tumors had lung metastases, whereas all treated mice were metastasis-free, thus suggesting that this 
PDX could be further developed to analyze the effect of therapeutic treatments on metastatic spread of EW.
Discussion
We generated a large panel of bone sarcoma PDX, namely OS and EW, comprising a sizeable number of PDX 
from pediatric patients, thus creating a powerful tool for future prognostic and sensitivity analyses. All the PDXs 
described in this work are available for distribution, within the limits of the informed consent of patients, upon 
the establishment of a standard material transfer agreement.
Figure 2. Unsupervised clustering using all (40 K) genes and all specimens (A). Correlation between OS (B) 
and EW (C) samples calculated using the whole gene expression profile obtained from microarray analysis. 
Correlation indexes (Pearson’s r) was used to perform the hierarchical clustering of samples (Euclidean 
distance). Abbreviations: PC, primary in vitro culture; F0, patient’s specimen; F1, PDX at first in vivo passage; 
F6, PDX at sixth in vivo passage.
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Figure 3. (A) Heatmap of OS samples obtained using the list of 397 genes (see Supplementary Table 3) that 
are differentially expressed (adjusted p < 0.05) between primary tumors and PDX. Genes (columns) and 
samples (rows) were grouped by hierarchical clustering (Manhattan correlation). High- and low- expression is 
normalized to the average expression across all samples. (B) Map of “Immune response_Antigen presentation 
by MHC class I” pathway, which is the top scored (lowest p value) map based on Genego pathway enrichment 
analysis. Experimental data (OS PDX/primary tumor ratio) from microarray experiments are visualized on the 
map as thermometer-like figures. Significantly upregulated genes show upward, red bars, while down-regulated 
genes show downward, blue bars.
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PDX have been so far successfully established and characterized for many different cancer types, such as 
colorectal38,39, pancreatic40, lung41, breast42–44, ovarian45,46 and endometrial cancer47. Together with other bone 
tumor PDX series17,28,48–53, the systematic collection of PDX from bone sarcomas, including EW, allows the gen-
eration of a wider repository of reliable models for testing drug sensitivity, biomarkers evaluation, or tuning of a 
personalized therapeutical schedule. A comparison of our series of bone sarcoma PDXs with those recently pub-
lished by Rainusso et al.53 and Stewart et al.28 shows a lower (but not statistically significant) global percentage of 
engraftment (32% vs 54% vs 45%, respectively). These differences might result both from differences in the tech-
niques of tumor implantation and from differences in the clinical series. For what concerns the former, Stewart 
et al.28 used enzymatic dissociation of clinical samples to obtain a cellular suspension that was then injected 
orthotopically in mice together with an extracellular matrix preparation, whereas in the paper by Rainusso et 
al.53 and in the present work tumor fragments were implanted subcutaneously. Regarding clinical series, both 
Rainusso et al.53 and Stewart et al.28 had a higher percentage of OS than our series, and in all cases OS showed a 
higher engraftment rate than EW. However, the relative proportion of OS vs EW within each clinical series does 
not seem to explain the higher engraftment rate reported by Rainusso et al.53 and Stewart et al.28, because they 
had higher engraftment rates than ours, in particular within the OS group. A further relevant aspect that might 
contibute to the observed differences was the different proportion of clinical samples from treated OS patients in 
each clinical series. As therapeutic treatments and patient’s responses were difficult to compare among the three 
series, the most straightforward comparison is based on untreated patients. Under this respect, both Rainusso et 
al.53 and our series showed comparable engraftment rates (42% vs 50%), whereas the series of Stewart et al.28 was 
not comparable because it contained only one untreated OS patient. A further element of difference among the 
three clinical series was the proportion of pediatric vs adult cases. Both Rainusso et al.53 and Stewart et al.28 only 
studied pediatric bone sarcomas, whereas our series included a mix of pediatric and adult cases, both among OS 
and EW. However, this difference should not affect the differences in engraftment, because we found that pediatric 
and adult bone sarcomas did not significantly differ in the engraftment rates (Table 1).
Two important properties of our PDX panel were revealed by in-depth molecular and morphological studies: 
a faithful reproduction of the phenotypic features of the human tumor of origin and a considerable stability at 
least until the 6th in vivo generation. A direct comparison of the gene expression profiles of the PDX and of the 
cell culture obtained from the same patient showed that the PDX better reflected the molecular features of the 
human tumor than the cell culture. Although the underlying cause of cell lines limited predictive value is not 
fully understood10,54,55, evidence suggests that the process of generating in vitro cancer cultures results in major 
and irreversible alterations of biological properties, including gain and loss of genetic information, alteration in 
growth and invasion properties, and loss of specific cell populations10,56,57.
Figure 4. Inhibition of PDX-EW#3 and PDX-EW#2 (as indicated) tumor growth by a combination of 
anti-CD99 diabody C7 and irinotecan. Groups of 5–6 mice were treated as described under Material and 
Methods. Statistical comparisons: *slope of linear regression significantly different from untreated, p < 0.05; 
**slope of linear regression significantly different from all other groups, p < 0.01 at least; §slope of linear 
regression significantly different from untreated and from C7, p < 0.01 at least, p = 0.17 versus irinotecan.
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The faithfulness of preclinical models has been considerably debated in recent times as one of the reasons 
of the poor translatability of preclinical endeavors into effective therapeutic approaches14,57,58. This problem is 
particularly evident in OS and EW, in which therapeutic options are often inadequate in relapsed disease, but 
clinical evidence of substantial advancements is lacking1–3. The problem is further worsened by the rarity of 
these two malignancies, which slows down any potential scientific improvement resulting from basic or transla-
tional research and results in neglect by big pharma companies. The availability of both pediatric and adult PDX 
will allow the evaluation of therapeutic regimes tailored to pediatric tumors, which are currently treated with 
scaled-down protocols originally designed for adult tumors59,60. Some recent findings report new drugs sensitivity 
tested also in EW and OS PDX models57,61–65, further sustaining the potential of these models. We investigated 
here a combination of irinotecan and dAbd C7 treatment in two EW-PDX. Our results suggest that the addition 
of the anti-CD99 treatment could be beneficial when irinotecan alone is less effective, possibly depending on 
tumor growth rate. As we tested only two PDX, these conclusions will need to be confirmed in a larger series of 
preclinical models.
conclusion
In conclusion, expandable, shareable and reliable preclinical models are a highly desirable tool for the identifica-
tion of predictive biomarkers and for the evaluation of effective treatment strategies.
Data Availability
The datasets generated during and/or analysed during the current study are available in the ArrayExpress repos-
itory (accession E-MTAB-7568).
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